Cyclacel Pharmaceuticals, INC 10-Q quarterly reports

Bio Green Med Solution, Inc. has completed a strategic pivot from biopharmaceuticals to fire safety and distribution, reporting a significantly reduced net loss for the nine months ended September 30, 2025, following key acquisitions and divestitures.

Cyclacel Pharmaceuticals, Inc. is undergoing a major strategic shift, liquidating its biopharma subsidiary and planning to acquire industrial assets, while facing a going concern warning and a new lawsuit.

Cyclacel Pharmaceuticals reports its Q1 2025 results, highlighting a strategic shift following the liquidation of its UK subsidiary and ongoing efforts to address going concern issues.

Cyclacel Pharmaceuticals reported its Q3 2024 financial results, highlighting ongoing clinical trials and financial challenges, including a Nasdaq delisting notice.

Cyclacel Pharmaceuticals reported its financial results for the second quarter of 2024, highlighting ongoing clinical trials and financial challenges.

Cyclacel Pharmaceuticals reported a net loss of $2.9 million for the first quarter of 2024, while highlighting progress in its clinical programs and recent financing activities.